Biomarin Pharmaceutical (BMRN) EPS (Weighted Average and Diluted): 2009-2025
Historic EPS (Weighted Average and Diluted) for Biomarin Pharmaceutical (BMRN) over the last 12 years, with Sep 2025 value amounting to -$0.16.
- Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) fell 129.09% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.67, marking a year-over-year increase of 60.84%. This contributed to the annual value of $2.21 for FY2024, which is 154.02% up from last year.
- As of Q3 2025, Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) stood at -$0.16, which was down 113.01% from $1.23 recorded in Q2 2025.
- Biomarin Pharmaceutical's 5-year EPS (Weighted Average and Diluted) high stood at $1.23 for Q2 2025, and its period low was -$0.32 during Q4 2021.
- In the last 3 years, Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) had a median value of $0.46 in 2024 and averaged $0.46.
- In the last 5 years, Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) tumbled by 390.91% in 2021 and then soared by 7,688.88% in 2023.
- Over the past 5 years, Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.32 in 2021, then soared by 99.59% to -$0.00 in 2022, then soared by 7,688.88% to $0.10 in 2023, then skyrocketed by 550.00% to $0.65 in 2024, then slumped by 129.09% to -$0.16 in 2025.
- Its last three reported values are -$0.16 in Q3 2025, $1.23 for Q2 2025, and $0.95 during Q1 2025.